Adalvo announces successful Pivotal BE trial on Teriflunomide development

18 January 2021

Adalvo is happy to claim positive pivotal PK result on its Teriflunomide development which will soon be a new addition to our high-value product portfolio to our customers.

Pivotal trial was carried out on Teriflunomide 14mg film-coated tablets (Adalvo) vs Aubagio® 14mg film-coated tablets (Sanofi). Given our successful results Adalvo will proceed forward and finalize on our generic dossier as soon as technically possible. Leveraging on Teriflunomide we further pave the road for our highly distinguished CNS portfolio that already includes many high-value, complex and differentiated assets.

Adalvo is finalizing on a generic equivalent version of Aubagio® film-coated tablets that has been co-developed with one of our strategic partners. Aubagio® is a blockbuster specialty drug originally developed by Sanofi and is indicated for the treatment of relapsing remitting multiple sclerosis. The brand is currently selling $2.4 billion globally as reported by IQVIA.

Partner up now!  

Adalvo is very excited about many other interesting products in development and the positive news on this product gives us even bigger reason to look forward to the bright future ahead of us. Please contact our BD Directors for your markets for further information.

arna.hansen@adalvo.com – FR, AT, CH, Nordics, GR, Canada, South Africa, Australia
martin.paunov@adalvo.com – MENA
paulo.rodriguez@adalvo.com – ES, IT, DE, LATAM,
margarida.neves@adalvo.com – UK, PT, CEE CIS, RU, Brazil
arni.baldursson@adalvo.com - APAC

Disclaimer: Teriflunomide which is subject to patent protection is currently not offered or made available in countries where patents are in force.